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Introduction
Vaginitis and vaginosis are gynecologic diseases charac-
terized primarily by the complaint of abnormal discharge.
Representative entities are genital candidiasis, vaginal
trichomoniasis and bacterial vaginosis (BV). Genital can-
didiasis and vaginal trichomoniasis are attributable to
particular microbes, while bacterial vaginosis is induced by
collapse of the indigenous microbial ﬂora and is not
attributable to any particular microbe. Table 1 lists the
major features of vaginitis and vaginosis. The diagnosis of
these conditions should be based on general assessment of
the properties of secretions (a major complaint) as well as
signs of vaginal mucosa inﬂammation, presence/absence of
an amine odor, the pH of vaginal secretions, cells contained
in the secretions, and so on.
Concept
Bacterial vaginitis is a condition in which a reduction in the
density of bacteria of Lactobacillus spp. within the vagina
has resulted in abnormal proliferation of various aerobes
and anaerobes within the normal vagina [1]. In other
words, the term nonspeciﬁc vaginitis or bacterial vaginitis
is used to indicate vaginitis in which no particular microbes
(Candida spp., Trichomonas spp., Neisseria gonorrhoeae,
etc.) are isolated. The WHO criteria for the diagnosis of
bacterial vaginitis are shown in Table 2. Although the
WHO criteria set the pH of vaginal secretions at more than
4.5, in actual practice, it is desirable to set the pH above 5.0
when making a diagnosis of bacterial vaginitis.
The vagina of a healthy mature female harbors various
indigenous bacteria, of which 75–95% are reportedly
Lactobacillus spp. The vagina is an organ equipped with
a very high self-cleaning capability, which owes much to
these so-called ‘‘beneﬁcial bacteria’’. Bacteria of Lacto-
bacillus spp. form lactic acid through degradation of
glycogen, and they prevent invasion by unwanted bac-
teria by keeping the vagina acidic (pH less than 4.5). The
predominance of Lactobacillus spp. in the vagina is more
marked than the predominance of intestinal bacterial
ﬂora within the intestine. Lactobacillus spp. constitute
normal bacterial ﬂora in the vagina and thus play an
important role. Previously, L. acidophilus was considered
to be a major bacterium of Lactobacillus spp. found
in the vagina. However, it was recently shown that
L. cerispatus, which has a high H2O2-producing capa-
bility, and certain other bacteria are predominant in the
vagina [2].
Bacterial vaginosis was previously considered to be an
infection primarily involving anaerobes. It was recently
shown that this condition is not associated with any partic-
ular microbe but rather is attributable to mixed infection
involving aerobes (Streptococcus agalactiae, Escherichia
coli, Gardnerella vaginalis, etc.), anaerobes (Peptostrepto-
coccus spp., Finegoldia spp., Parvimonas spp., Peptoniph-
ilus spp., Anaerococcus, Atopobium spp. (A. Vaginal, etc.),
Mobiluncus spp., Bacteroides spp., Prevotella spp., etc.),
Mycoplasma spp. (Mycoplasma hominis, M. Genitalium),
Ureaplasma spp. (Ureaplasma urealyticum, etc.), and so on
[3, 4]. Recently, attempts have been made to identify bac-
teria in discharged ﬂuid samples using combinations of PCR
ampliﬁcation of bacterial 16S rDNA, clone analysis, bac-
terium-speciﬁc PCR of 16S rDNA, ﬂuorescent in situ
hybridization, etc. These efforts revealed that females with
bacterial vaginosis can have complex vaginal infections due
to many previously unknown bacterial strains, including 3
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bacteria of Clostridium spp. closely related to bacterial
vaginosis [5].
Bacterial vaginosis due to disturbed vaginal bacterial
ﬂora can be characterized by minimal signs of inﬂamma-
tion and inability to identify the pathogen. Most genital
infections affecting females are also attributable to dis-
turbed vaginal bacterial ﬂora. If the unwanted bacteria
proliferating after disturbance of the bacterial ﬂora ascend
and pass through the uterine cervix, they can induce
endometritis. If these bacteria ascend further, they can
cause salpingitis, pelvioperitonitis, etc.
Bacterial vaginosis in pregnant women is associated
with chorioamnionitis, pre-term delivery of low-birth-
weight infants, puerperal endometritis and so on [6]. If
bacterial vaginosis develops in the third trimester of
pregnancy, it can induce premature labor and infections of
newborns such as pneumonia, meningitis and bacteremia.
Aging-related reductions in estrogen secretion can cause
vaginal wall atrophy. If vaginal injury or vaginitis develops
in a women with vaginal wall atrophy as a result of having
sexual intercourse, it is likely to cause small red or bloody
spots in the vaginal wall, cervix, etc. This condition is
called ‘‘atrophic vaginitis (senile vaginitis)’’ and is distinct
from bacterial vaginosis.
Diagnosis
Although the diagnosis of bacterial vaginosis is often made
empirically, it is advisable to diagnose this condition
objectively on the basis of WHO criteria for diagnosing
bacterial vaginosis, and so on.
The method of Nugent, which involves gram staining of
samples (Table 3) allows objective diagnosis of bacterial
vaginosis. In addition, this method allows the identiﬁcation
of individuals with borderline conditions (neutral judgment
cases). The diagnosis of this condition should be based on
general assessment of the properties of secretions (a major
complaint) as well as signs of vaginal mucosa inﬂamma-
tion, presence/absence of an amine odor, the pH of vaginal
secretions, cells contained in the secretions, and so on.
Treatment
A basic local therapy for this condition is once daily
administration of a chloramphenicol (CP) vaginal tablet
(100 mg) or a metronidazole vaginal tablet (250 mg),
which is to be inserted into the posterior vaginal fornix
(Table 4). One treatment cycle lasts for 6 days [7]. Alter-
natively, clindamycin (CLDM) cream (2%, 5 g), prepared
at hospital or clinic, can be inserted into the vagina at
bedtime for 3–5 days.
To enhance the therapeutic efﬁcacy of these drugs, the
vagina should be washed with sterile distilled water or
physiological saline during the early stages of treatment. If
the vaginal discharge is abundant or malodorous, the
vagina should be washed with 0.025% benzalkonium
chloride solution or 10% povidone iodine solution. Vaginal
washing is important for improving drug efﬁcacy during
Table 2 WHO criteria for the diagnosis of bacterial vaginitis
1. Vaginal secretions are thin and homogenous
2. Vaginal secretions dissolved in physiological saline contain clue cells with granular cytoplasm
3. Addition of one drop of 10% KOH to the vaginal secretions produces an amine odor
4. The vaginal secretion pH is 4.5 or higher
If at least 3 of the criteria listed above are satisﬁed, a diagnosis of bacterial vaginosis can be made
Table 1 Major features of vaginitis and vaginosis
Feature Genital candidiasis Vaginal trichomoniasis Bacterial vaginitis
Causative organisms Candida spp. Trichomonas vaginalis Aerobes, anaerobes
Signs of inﬂammation Present Present (intense) Absent
Appearance of secretions Cheese-like, pultaceous, white Puriform, foamy, occasionally
bloody
Homogeneous and gray
pH of secretions Below 4.5 Often over 5.0 Often over 5.0
Amine odor Absent Occasionally present Present
Cells in secretions Leukocytes, squamous cells Leukocytes, predominantly Clue cells (leukocytes, rarely)
Others Indigenous ﬂora often remains intact
(no decrease in Lactobacillus spp.)
Often decreased Lactobacillus spp.
(occasionally complicated by
bacterial vaginosis)
Decreased Lactobacillus spp.
(occasionally complicated by
STI)
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the early stages of treatment. However, it is not advisable
to wash the vagina at every visit to the clinic because this
can reduce the density of Lactobacillus spp. within the
vagina.
An available systemic drug therapy is oral metronida-
zole for 7 days at a daily dose level of 1 g (in two divided
doses). In pregnant women and other special cases, 7-day
oral treatment with ampicillin (ABPC) or amoxicillin
(AMPC) (drugs of the penicillins) at a dose of 2000 mg (in
4 divided doses) is sometimes effective. However, none of
these therapies are as yet well-established.
Because it has been shown that bacterial vaginosis
during pregnancy is associated with abortion and pre-
mature labor, active treatment with vaginal tablets is nee-
ded for cases satisfying the WHO criteria for diagnosis.
Treatment of atrophic vaginitis, which has a high inci-
dence among elderly women, is usually carried out in a
manner similar to that for bacterial vaginosis, but treatment
often involves the use of estriol vaginal tablets or oral drug
therapy. In patients presenting with intense climacteric
symptoms, hormone replacement therapy, oriental medi-
cines (Kampo medicine), etc., are sometimes used in
combination with these therapies.
Estrogen secretion declines with age. Aging-related
reductions in estrogen secretion can cause vaginal wall
atrophy. If vaginal injury or vaginitis develops in a women
with vaginal wall atrophy as a result of having sexual
intercourse, it is likely to cause small red or bloody spots in
the vaginal wall, cervix, etc.
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Table 3 Criteria for the diagnosis of bacterial vaginosis based on
gram staining of vaginal secretions (Nugent’s method)
Type Bacterial
count/visual
ﬁeld
Score
Lactobacillus type 0 4
\1 3
1–4 2
5–30 1
[30 0
Gardnerella type (including
gram-negative small
rods such as Prevotella)
0 0
\1 1
1–4 2
5–30 3
30 4
Mobiluncus type 0 0
\1 1
1–4 1
5–30 2
[30 2
Total score
Methods: The vaginal secretion is smeared onto a glass slide,
followed by gram staining; under an oil-immersion lens (1,0009), the
morphologically characteristic Lactobacillus, Gardnerella and
Mobiluncus organisms per visual ﬁeld are counted; each bacterial
count is applied to the table shown above, to calculate the total sore
Judgment: Total score: 0–3 (normal), 4–6 (neutral), over 7 (bacterial
vaginosis) (if the total score is over 4, it is advisable to culture the
sample to check for microbes associated with bacterial vaginosis,
including obligate anaerobes)
Table 4 Examples of medications for bacterial vaginitis
1. Chloramphenicol (Chlomy vaginal tablet) 100 mg, 1 tablet/day,
one dose/day (inserted into the vagina), 6 days
2. Metronidazole (Flagyl vaginal tablet) 250 mg, 1 tablet/day, one
dose/day (inserted into the vagina), 6 days
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